Vivani Medical to Initiate Clinical Study in Australia for Miniature NPM-115

Vivani Medical to Initiate Clinical Study in Australia for Miniature NPM-115

By, Admin 15 July 2024

Vivani Medical to initiate clinical study in Australia for miniature, long-term, GLP-1 obesity implant programme, NPM-115

Overview

Vivani Medical, Inc., an innovative, biopharmaceutical company developing novel, long-term drug implants, announced that it expects to initiate the first clinical study in the NPM-115 programme in the fourth quarter of 2024 in Australia, pending regulatory clearance in that country. The NPM-115 clinical programme will evaluate the investigational 6-month GLP-1 implant for chronic weight management in patients who are either obese or overweight with a related comorbidity.

Words from the CEO: Vivani Medical

  • In February, our company announced that we were re-prioritizing the development of our GLP-1 implants to focus on the treatment of obesity and chronic weight management in response to the significant medical need and unprecedented market demand,” said Adam Mendelsohn, Ph.D., Vivani’s president and chief executive officer. 
  • Today we can report that our first-in-human study, LIBERATE-1, is expected to enroll patients who are obese or overweight to primarily support NPM-115’s development programme. We anticipate initiating this clinical study in Australia later this year.
  • Dr. Mendelsohn continued: “The results of LIBERATE-1 may support initiation of a subsequent clinical study, pending regulatory clearance, to explore higher and potentially more effective doses of our exenatide implant on weight and tolerability in obese or overweight patients. 
  • Once the target dose is identified, we intend to study an implant at that dose over the full 6-month duration, over which our implant has already demonstrated encouraging results in preclinical animal models. Additionally, we believe the results of LIBERATE-1 may provide clinical validation of our NanoPortal drug delivery technology to support a broader application of the technology in the treatment of chronic diseases.

About LIBERATE-1

  • LIBERATE-1 will be a randomized investigation of the safety, tolerability and pharmacokinetic profile of the exenatide NanoPortal implant in obese or overweight patients. 
  • The study will enroll patients who will be titrated on weekly semaglutide injections (Wegovy) for 8 weeks (0.25 mg/week for 4 weeks followed by 0.5 mg/week for 4 weeks) before being randomized to receive a single administration of Vivani’s exenatide implant (n=8), weekly exenatide injections Bydureon BCise (n=8), or weekly 1 mg semaglutide injections (n=8) for a 9-week treatment duration. 
  • The exenatide implant to be used in LIBERATE-1 is expected to produce comparable exenatide exposure levels as Bydureon BCise. 
  • Changes in weight will be measured. The trial is expected to initiate later this year with data projected to be available in 2025.

Positive Weight Loss Outcome

On February 28, 2024, Vivani announced positive preclinical weight loss data from its exenatide implant in support of its NPM-115 development programme which was comparable to semaglutide injections (the active pharmaceutical ingredient in Ozempic/Wegovy) and a strategic shift to prioritize its obesity portfolio.

IND Clearance by FDA

  • On June 13, 2024, Vivani announced that the US Food and Drug Administration (FDA) cleared its Investigational New Drug for its exenatide implant to be studied in patients with type 2 diabetes in support of the NPM-119 development programme. 
  • The company previously announced an intention to initiate the first study in the NPM-119 programme in the second half of this year. 
  • As a result of reprioritizing the focus of its GLP-1 implants on the treatment of obesity and chronic weight management, the Company plans to first pursue the NPM-115 study. 
  • Dr. Mendelsohn noted that the NPM-115 programme utilizes the same exenatide implant as NPM-119, and the only difference is the population to be studied.

Application for Clinical Trial

  • Vivani plans to submit an application to a Human Research Ethics Committee in Australia to support the initiation of the Company’s first-in-human study supporting the NPM-115 programme in that country. 
  • If available, Vivani intends to utilize research and development incentives and rebates from the Australian government in order to defray a portion of the costs from the trial. 
  • Since clinical studies conducted in Australia comply with the International Conference on Harmonization guidelines and data generated in Australia are acceptable to the FDA and other regulatory authorities, Vivani anticipates use of relevant clinical data generated in Australia to support regulatory submissions in other geographies including the US. 
  • Additional guidance will be provided as new information becomes available.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!